Holmlund U, Bengtsson A, Nilsson C, Kusoffsky E, Lilja G, Scheynius A, Sverremark-Ekström E
Department of Medicine, Unit of Clinical Allergy Research, Karolinska Hospital and Institutet, Stockholm, Sweden.
Clin Exp Allergy. 2003 Nov;33(11):1531-6. doi: 10.1046/j.1365-2222.2003.01792.x.
The CD30 molecule has been linked to Th2 responses. Furthermore, elevated levels of the soluble form of CD30 (sCD30) in blood as well as of the expression of CD30 on the plasma membrane of T cells are associated with atopic disease.
To assess the potential usefulness of sCD30 levels as a prognostic indicator of and/or diagnostic marker for the development of atopic disease in children.
sCD30 levels in cord blood and peripheral blood from 36 2-year-old (10 atopic and 26 non-atopic) and 74 7-year-old (35 atopic and 39 non-atopic) children were determined employing an ELISA procedure. Atopy was diagnosed on the basis of clinical evaluation in combination with a positive skin prick test.
No significant correlation between sCD30 levels in cord blood and the development of atopic disease at 2 or 7 years of age was observed. At 7 years of age, the circulating sCD30 levels in children with atopic disease (median 41 U/mL, range 6-503 U/mL) did not differ from the corresponding values for non-atopic subjects (median 41 U/mL, range 8-402 U/mL). The same was true for children at 2 years of age. Furthermore, the sCD30 levels of children who had developed atopic eczema/dermatitis syndrome by the age of 7 years (median 49 U/mL, range 14-503 U/mL) were not significantly elevated in comparison with those of the non-atopic children. Finally, neither sCD30 levels in cord blood nor peripheral blood at 2 or 7 years of age could be linked to a family history of atopy.
These findings indicate that the sCD30 concentration in cord blood is not a reliable prognostic indicator of, nor a useful diagnostic marker for, atopic disease in children up to 7 years of age. If such correlations do exist, they might be masked by age-dependent variations in the circulating levels of sCD30, which may reflect individual differences in the maturation of children's immunological responses.
CD30分子与Th2反应有关。此外，血液中可溶性CD30（sCD30）水平的升高以及T细胞膜上CD30的表达与特应性疾病相关。
评估sCD30水平作为儿童特应性疾病发生的预后指标和/或诊断标志物的潜在实用性。
采用ELISA法测定36名2岁儿童（10名特应性和26名非特应性）和74名7岁儿童（35名特应性和39名非特应性）脐带血和外周血中的sCD30水平。特应性根据临床评估结合皮肤点刺试验阳性来诊断。
未观察到脐带血中sCD30水平与2岁或7岁时特应性疾病的发生之间存在显著相关性。7岁时，特应性疾病儿童的循环sCD30水平（中位数41 U/mL，范围6 - 503 U/mL）与非特应性受试者的相应值（中位数41 U/mL，范围8 - 402 U/mL）无差异。2岁儿童也是如此。此外，与非特应性儿童相比，7岁时患特应性湿疹/皮炎综合征的儿童的sCD30水平（中位数49 U/mL，范围14 - 503 U/mL）没有显著升高。最后，脐带血或2岁及7岁时外周血中的sCD30水平均与特应性家族史无关。
这些发现表明，脐带血中sCD30浓度不是7岁以下儿童特应性疾病的可靠预后指标，也不是有用的诊断标志物。如果确实存在这种相关性，它们可能会被sCD30循环水平的年龄依赖性变化所掩盖，这可能反映了儿童免疫反应成熟过程中的个体差异。
